At least that's what Shionogi Pharma is hoping. The Japanese drugmaker just released new data about its propellant spray and the findings suggest men will get a needed boost - those who sprayed the tip of their penis five minutes before having sex lasted 3-plus minutes compared with 34 seconds before the study began, and 56 seconds among the guys who were given a placebo. The results may not be huge, but every second counts.
The data actually combine two studies involving 1,092 men who were asked to have at least three sexual encounters and suffered premature ejaculation at least twice prior to the Shionogi experiment (see the press release). The International Society for Sexual Medicine defines PE as the inability to delay ejaculation for more than 1 minute after vaginal penetration and, supposedly, up to one-third of US men suffer.
Shionogi measured success two ways - the Intravaginal Ejaculatory Latency Time, as discussed above, and a patient survey that asked about distress, control and satisfaction. The men responded that PSD502 yielded improvement across the board, although so did the men on placebo, just not to the same extent. Side effects included 3.1 percent reporting loss of erection and 5 percent of the partners complaining of a burning sensation. Why that burning feeling? Ira Sharlip, a Shionogi consultant and clinical professor of urology at the University of California, San Francisco, posits that women "were having more intercourse than they usually have."
The spray, by the way, combines lidocaine and prilocaine, two local anesthetics, along with the propellant, atlhough Shionogi has no idea how it works. Nonetheless, Shionogi hopes to capitalize on a market that, like erectile dysfunction, is sure to generate substantial publicity and interest, especially since there is nothing currently available in the US for PE. Shionogi, in fact, worked overtime this past weekend at the American Urological Association to garner coverage of its data.
Nonetheless, the drugmaker can still expect some skepticism, despite the ISSM definition. "It would seem to be an entirely subjective measure, so that one man may say that it’s within 2 minutes and another may say that it’s within 10 minutes. How much is culturally determined?" says Joel Lexchin, a professor at York University's School of Health Policy & Management. "This strikes me as a bonanza for any company that can get a drug approved for this condition, since the company will try and set a standard time and any man that doesn’t meet that time is a potential user of the product."